Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.64 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.45 |
| ▸ | MELK | Q14680 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5667022 | 0.93 | GRM5 (0.68) | GRM5MKNK1HTR1AHTR7GRM4 | |
| SCHEMBL5667534 | 0.90 | GRM5 (0.71) | GRM5MKNK1HTR1AHTR7GRM4 | |
| SCHEMBL5670076 | 0.88 | GRM5 (0.62) | GRM5MKNK1HTR1AHTR7MKNK2 | |
| SCHEMBL5662955 | 0.84 | GRM5 (0.51) | GRM5MKNK1MKNK2GRM4PDE10A | |
| SCHEMBL15945076 | 0.81 | GRM5 (0.66) | GRM5GRM4CYP2A6PDE10AKDR | |
| SCHEMBL3919683 | 0.81 | GRM5 (0.67) | GRM5MKNK1HTR1AHTR7GRM4 | |
| SCHEMBL3921029 | 0.81 | GRM5 (0.67) | GRM5MKNK1HTR1AHTR7GRM4 | |
| SCHEMBL30795074 | 0.81 | GRM5 (0.67) | GRM5MKNK1HTR1AHTR7GRM4 | |
| SCHEMBL3924775 | 0.81 | GRM5 (0.62) | GRM5MKNK1HTR1AHTR7MKNK2 | |
| SCHEMBL30795898 | 0.81 | GRM5 (0.62) | GRM5MKNK1HTR1AHTR7MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100387594-C | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO INC (US) | 2008-05-14 | — | — | CN | claimed |
| US-20060194807-A1 | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. | 2006-08-31 | — | — | US | claimed |
| CN-1795184-A | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO INC (US) | 2006-06-28 | — | — | CN | claimed |
| EP-1613614-A2 | DI-ARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2006-01-11 | — | — | EP | claimed |
| WO-2004089303-A2 | DI-ARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089303-A2 | DI-ARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194807-A1 | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | GRM5, GRM1, GRIK5 | GRM5 1/4885MKNK1 2084/4885MELK 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.